Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Primary research

Quercetin-induced inhibition and synergistic activity with cisplatin – a chemotherapeutic strategy for nasopharyngeal carcinoma cells

Authors: Maelinda Daker, Munirah Ahmad, Alan SB Khoo

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

Background

Nasopharyngeal carcinoma (NPC) is a unique tumour of epithelial origin with a distinct geographical distribution, genetic predisposition and environmental as well as dietary influence as aetiological factors. Standard NPC treatment regimes, such as radiotherapy and concurrent chemotherapy with cytotoxic drugs, can produce undesirable complications often associated with significant toxicity. Here, we report the effects of a widely distributed flavonoid, quercetin, on cell proliferation, apoptosis and cell cycle arrest. The effects of combining quercetin and cisplatin on human NPC cells were explored.

Methods

Cell proliferation was monitored by the dynamic, impedance-based cell analyzer (xCELLigence system) and the MTS assay. Ki67 proliferation antigen and fatty acid synthase (FASN) level was examined by Western blotting. Flow cytometry was also carried out to study the effects of quercetin on cell cycle and apoptosis status.

Results

At 100 μM, quercetin inhibited cell proliferation and decreased expression of FASN and Ki67 antigen. Cell cycle analysis revealed a substantial increase in the proportion of cells in the G2/M phase. We also demonstrated the enhanced cytotoxic effects of quercetin treatment in concomitant with the chemotherapeutic drug, cisplatin, in cultured NPC cells. The combination index (CI) value of quercetin-cisplatin combination was < 1, indicating synergism.

Conclusions

Our study showed that quercetin exhibited synergistic effects with cisplatin against NPC cells. Dose-reduction index (DRI) values > 1 implied the possibility of reducing the cisplatin dosage required to treat NPC, with the addition of quercetin. In turn, this could reduce the risk of cisplatin-associated toxicity. The potential of combining quercetin with cisplatin as a chemotherapeutic strategy for treatment of NPC should be explored further.
Appendix
Available only for authorised users
Literature
1.
Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet. 2005, 365: 2041-2054. 10.1016/S0140-6736(05)66698-6.CrossRefPubMed
2.
Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM: Nasopharyngeal carcinoma–review of the molecular mechanisms of tumorigenesis. Head Neck. 2008, 30: 946-963. 10.1002/hed.20833.PubMedCentralCrossRefPubMed
3.
Tao Q, Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 2007, 9: 1-24.CrossRefPubMed
4.
Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP: Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003, 39: 2121-2135. 10.1016/S0959-8049(03)00367-8.CrossRefPubMed
5.
Chen C, Zhou J, Ji C: Quercetin: A potential drug to reverse multidrug resistance. Life Sci. 2010, 87: 333-338. 10.1016/j.lfs.2010.07.004.CrossRefPubMed
6.
Murakami A, Ashida H, Terao J: Multitargeted cancer prevention by quercetin. Cancer Lett. 2008, 269: 315-325. 10.1016/j.canlet.2008.03.046.CrossRefPubMed
7.
Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV: Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem. 2005, 280: 5636-5645.CrossRefPubMed
8.
Zhang F, Cui Y, Cao P: Effect of quercetin on proliferation and apoptosis of human nasopharyngeal carcinoma HEN1 cells. J Huazhong Univ Sci Technolog Med Sci. 2008, 28: 369-372. 10.1007/s11596-008-0333-0.CrossRefPubMed
9.
Sharma H, Sen S, Singh N: Molecular pathways in the chemosensitization of cisplatin by quercetin in human and neck cancer. Cancer Biology & Therapy. 2005, 4: 949-955. 10.4161/cbt.4.9.1908.CrossRef
10.
Yoshida M, Yamamoto M, Nikaido T: Quercetin arrests human leukemic T-cells in late G1 phase of the cell cycle. Cancer Res. 1992, 52: 6676-6681.PubMed
11.
Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H, Aoike A: The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett. 1990, 260: 10-13. 10.1016/0014-5793(90)80053-L.CrossRefPubMed
12.
Dihal AA, Woutersen RA, van Ommen B, Rietjens IMCM, Stierum RH: Modulatory effects of quercetin on proliferation and differentiation of the human colorectal cell line Caco-2. Cancer Lett. 2006, 238: 248-259. 10.1016/j.canlet.2005.07.007.CrossRefPubMed
13.
Hofmann J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H: Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer. 1990, 45: 536-539. 10.1002/ijc.2910450327.CrossRefPubMed
14.
Menendez JA, Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007, 7: 763-777. 10.1038/nrc2222.CrossRefPubMed
15.
Chou T-C: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006, 58: 621-681. 10.1124/pr.58.3.10.CrossRefPubMed
16.
Cross HJ, Tilby M, Chipman K, Ferry DR, Gescher A: Effect of quercetin on the genotoxic potential of cisplatin. Int J Cancer. 1996, 66: 404-408. 10.1002/(SICI)1097-0215(19960503)66:3<404::AID-IJC23>3.0.CO;2-9.CrossRefPubMed
17.
Ferry DR, Smith A, Malkhandi J, Fyfe DW, De Takats PG, Anderson D, Baker J, Kerr DJ: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996, 2: 659-668.PubMed
18.
Hollman PCH, van Trijp JMP, Mengelers MJB, de Vries JHM, Katan MB: Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett. 1997, 114: 139-140. 10.1016/S0304-3835(97)04644-2.CrossRefPubMed
19.
Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Büchler MW: Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010, 37: 551-561.PubMed
20.
Lamson DW, Brignall MS: Antioxidants and Cancer III: Quercetin. Alternative Medicine Review. 2000, 5: 196-208.PubMed
21.
Hollman PCH, van Trijp JMP, Buysman MNCP, van der Gaag MS, Mengelers MJB, de Vries JHM, Katan MB: Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 1997, 418: 152-156. 10.1016/S0014-5793(97)01367-7.CrossRefPubMed
22.
Lee J, Mitchell AE: Pharmacokinetics of quercetin absorption from apples and onions in healthy humans. J Agric Food Chem. 2012, 60: 3874-3881. 10.1021/jf3001857.CrossRefPubMed
23.
Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M: Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol. 2001, 41: 492-499. 10.1177/00912700122010366.CrossRefPubMed
24.
Erlund I, Kosonen T, Alfthan G, Mäenpää J, Perttunen K, Kenraali J, Parantainen J, Aro A: Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol. 2000, 56: 545-553. 10.1007/s002280000197.CrossRefPubMed
25.
Kuhlmann MK, Horsch E, Burkhardt G, Wagner M, Köhler H: Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin. Arch Toxicol. 1998, 72: 536-540. 10.1007/s002040050539.CrossRefPubMed
26.
Jakubowicz-Gil J, Paduch R, Piersiak T, Glowniak K, Gawron A, Kandefer-Szerszeń M: The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol. 2005, 69: 1343-1350. 10.1016/j.bcp.2005.01.022.CrossRefPubMed
27.
Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Bonanno G, De Vincenzo R, Ferrandina G, Maggiano N, Capelli A, Mancuso S: Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). Gynecol Oncol. 1992, 45: 13-19. 10.1016/0090-8258(92)90484-Z.CrossRefPubMed
28.
Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH, Lau WH: Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer. 1980, 26: 127-132. 10.1002/ijc.2910260202.CrossRefPubMed
29.
Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM, Lee JC: Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 1999, 83: 121-126. 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F.CrossRefPubMed
30.
Chan SY-Y, Choy K-W, Tsao S-W, Tao Q, Tang T, Chung GT-Y, Lo K-W: Authentication of nasopharyngeal carcinoma tumor lines. Int J Cancer. 2008, 122: 2169-2171. 10.1002/ijc.23374.CrossRefPubMed
Metadata
Title
Quercetin-induced inhibition and synergistic activity with cisplatin – a chemotherapeutic strategy for nasopharyngeal carcinoma cells
Authors
Maelinda Daker
Munirah Ahmad
Alan SB Khoo
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-34

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Primary research

2-Methoxyestradiol-bis-sulphamate refrains from inducing apoptosis and autophagy in a non-tumorigenic breast cell line

Primary research

Evaluation of antiproliferative and anti-inflammatory activities of methanol extract and its fractions from the Mediterranean sponge

Primary research

Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

Primary research

Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo

Primary research

Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall

Primary research

Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits